{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:49:09Z","timestamp":1793836149786,"version":"4.6.1"},"reference-count":22,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Bialystok"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The aim of this study was to evaluate the diagnostic usefulness of two non-invasive, validated, and patented markers of liver fibrosis, the Hepascore and FibroTest, in patients with primary sclerosing cholangitis (PSC). The study group consisted of 74 PSC patients and 38 healthy subjects. All patients had a liver biopsy. The Hepascore and FibroTest were calculated using specific algorithms. The ANOVA rank Kruskal\u2013Wallis test revealed differences in the Hepascore and FibroTest between patients divided according to histological stage (p &lt; 0.001 for both comparisons). The Hepascore and FibroTest had significantly higher results in patients with significant fibrosis (F \u2265 2) in comparison to those with no significant fibrosis (F1) (p &lt; 0.001 for both tests) and higher values in patients with cirrhosis (F4) when compared to those without cirrhosis (F1\u2013F3) (p &lt; 0.001 for both comparisons). The Hepascore test showed a diagnostic sensitivity of 96.8%, a specificity of 100% for fibrosis (at cut-off 0.52) and a diagnostic sensitivity of 95.2%, and a specificity also of 100% for cirrhosis (at 0.80). The FibroTest in point 0.51 for the diagnosis of fibrosis obtained the following values: 58.6%, 90%, 89.5%, and 60%, respectively, and in point 0.73 for the diagnosis of cirrhosis: 42.9%, 100%, 100%, and 45.5, respectively. The Hepascore test reached an excellent diagnostic power in identifying both fibrosis and cirrhosis (AUC = 1.0). The FibroTest and Hepascore are highly valuable for the evaluation of the severity of liver fibrosis and cirrhosis in PSC patients and can be used as a primary screening method, allowing for a significant reduction in the need for liver biopsy. Both markers have the required sensitivity and specificity to detect liver fibrosis and cirrhosis and can be equally used in clinical practice, although the Hepascore seems to be a better test because it is more specific.<\/jats:p>","DOI":"10.3390\/jcm12247552","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T05:57:08Z","timestamp":1701928628000},"page":"7552","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC)"],"prefix":"10.3390","volume":"12","author":[{"given":"Bogdan","family":"Cylwik","sequence":"first","affiliation":[{"name":"Department of Pediatric Laboratory Diagnostics, Medical University of Bialystok, 15-274 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2051-1177","authenticated-orcid":false,"given":"Alicja","family":"Bauer","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7702-5148","authenticated-orcid":false,"given":"Ewa","family":"Gruszewska","sequence":"additional","affiliation":[{"name":"Department of Biochemical Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kacper","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases and Gastroenterology, Provincial Welded Hospital, 15-278 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Kazberuk","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases and Gastroenterology, Provincial Welded Hospital, 15-278 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6701-1861","authenticated-orcid":false,"given":"Lech","family":"Chrostek","sequence":"additional","affiliation":[{"name":"Department of Biochemical Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL Clinical Practice Guidelines: Management of cholestatic liver diseases","volume":"51","author":"Beuers","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7861\/clinmed.2020-0697","article-title":"An update on the management of cholestatic liver diseases","volume":"20","author":"Appanna","year":"2020","journal-title":"Clin. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s12072-011-9260-4","article-title":"Natural history of small duct primary sclerosing cholangitis: A case series with review of the literature","volume":"5","author":"Singal","year":"2011","journal-title":"Hepatol. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MCG.0b013e318157c614","article-title":"Characteristics and long-term prognosis of the autoimmune hepatitis\/primary sclerosing cholangitis overlap syndrome","volume":"43","author":"Luth","year":"2009","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1053\/j.gastro.2013.12.030","article-title":"Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis","volume":"146","author":"Corpechot","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.ultrasmedbio.2020.03.025","article-title":"Liver elastography in primary sclerosing cholangitis patients using three different scanner systems","volume":"46","author":"Mjelle","year":"2020","journal-title":"Ultrasound Med. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis\u2014A comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jfma.2020.08.019","article-title":"The non-invasive assessment of hepatic fibrosis","volume":"120","author":"Gheorghe","year":"2021","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.gtc.2019.02.002","article-title":"Liver fibrosis determination","volume":"48","author":"Lai","year":"2019","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, and FGF19 analogue, in primary sclerosing cholangitis: A multicentre, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00432479","article-title":"Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)","volume":"22","author":"Ludwig","year":"1978","journal-title":"Virchows Arch."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Poynard, T., Morra, R., Halfon, P., Castera, L., Ratziu, V., Imbert-Bismut, F., Naveau, S., Thabut, D., Lebrec, D., and Zoulim, F. (2007). Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol, 7.","DOI":"10.1186\/1471-230X-7-40"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep.22576","article-title":"Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease","volume":"49","author":"Naveau","year":"2009","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.17219\/acem\/28485","article-title":"The distribution of liver steatosis, fibrosis, steatohepatitis and inflammation activity in alcoholics according to FibroMax Test","volume":"24","author":"Gudowska","year":"2015","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Chrostek, L., Przekop, D., Gruszewska, E., Gudowska-Sawczuk, M., and Cylwik, B. (2019). Noninvasive indirect markers of liver fibrosis in alcoholics. BioMed Res. Int., 2019.","DOI":"10.1155\/2019\/3646975"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Przekop, D., Klapczynski, J., Grytczuk, A., Gruszewska, E., Gietka, A., Panasiuk, A., Golaszewski, S., Cylwik, B., and Chrostek, L. (2021). Non-invasive indirect markers of liver fibrosis after interferon-free treatment for hepatitis C. J. Clin. Med., 10.","DOI":"10.3390\/jcm10173951"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1478-3231.2005.01064.x","article-title":"Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease","volume":"25","author":"Suzuki","year":"2005","journal-title":"Liver Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1373\/clinchem.2005.048389","article-title":"Hepascore: An accurate validated predictor of liver fibrosis in chronic hepatitis C infection","volume":"51","author":"Adams","year":"2005","journal-title":"Clin. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-5926-3-8","article-title":"Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C","volume":"3","author":"Poynard","year":"2004","journal-title":"Comp. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1373\/clinchem.2007.085795","article-title":"Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages","volume":"9","author":"Poynard","year":"2007","journal-title":"Clin. Chem."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/24\/7552\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:34:37Z","timestamp":1760132077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/24\/7552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":22,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["jcm12247552"],"URL":"https:\/\/doi.org\/10.3390\/jcm12247552","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]}}}